Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor Antagonists - II. Pharmacological characterization in vivo

Neuropharmacology

Volumn 35, Issue 6, 1996, Pages 655-669

  Urwyler, Stephan ^a   Campbell, Elizabeth ^b   Fricker, Gert ^d   Jenner, Peter ^d   Lemaire, Michel ^c   McAllister, Kevin H ^a   Neijt, Hans C ^a   Park, Chun Kun ^e   Perkins, Martin ^b   Rudin, Markus ^c   Sauter, André ^c   Smith, Lance ^d   Wiederhold, Karl Heinz ^c   Müller, Werner ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Sandoz Institute for Medical Research   (United Kingdom)

^c Preclinical Research   (Switzerland)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Analgesia; Anticonvulsants; Biphenyl AP7 derivatives; Excitotoxicity; Ischemia; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; ALPHA AMINO 5 (PHOSPHONOMETHYL)[1,1' BIPHENYL] 3 PROPANOIC ACID; ANTICONVULSIVE AGENT; HEPTANOIC ACID DERIVATIVE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; QUINOLINIC ACID; SDZ 220 581; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN REGION; CONTROLLED STUDY; FEMALE; GLUCOSE UTILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MARMOSET; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SEIZURE;

EID: 0030174934     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00050-0     Document Type: Article

References (46)

1. Andersson T., Schultzberg M., Schwarcz R., Löve A., Wickman C. and Kristensson K. (1991) NMDA-receptor antagonist prevents measles virus-induced neurodegeneration. Eur. J. Neurosci. 3: 66-71.
2. Carlsson M. and Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13: 272-276.
3. Chapman A. G., Graham J. and Meldrum B. S. (1990) Potent oral anticonvulsant action of CPP and CPPene in DBA/2 mice. Eur. J. Pharmacol. 178: 97-99.
4. Choi D. W. and Rothman S. M. (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. A. Rev. Neurosci. 13: 171-182.
5. Davar G., Hama A., Deykin A., Vos B. and Makiewicz R. (1991) MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res. 553: 327-330.
6. De Montis M. G., Devoto P., Meloni D., Gambarana C., Giorgi G. and Tagliamonte A. (1992) NMDA receptor inhibition prevents tolerance to cocaine. Pharmacol. Biochem. Behav. 42: 179-182.
7. Fisher R. S. (1989) Animal models of the epilepsies. Brain Res. Rev. 14: 245-278.
8. Fonnum F. (1975) A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24: 407-409.
9. Foster A. C., Gill R. and Woodruff G. N. (1988) Neuroprotective effects of MK-801 in vivo: Selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J. Neurosci. 8: 4745-4754.
10. Foster A. C., Willis C. L. and Tridgett R. (1990) Protection against N-methyl-D-aspartate receptor - mediated neuronal degeneration in rat brain by 7-chlorokynurenate and 3-amino-1-hydroxy-pyrrolid-2-one, antagonists at the allosteric site for glycine. Eur. J. Neurosci. 2: 270-277.
11. Grant K. A., Valverius P., Hudspith M. and Tabakoff B. (1990) Ethanol withdrawal seizures and the NMDA receptor complex. Eur. J. Pharmacol. 176: 289-296.
12. Greenamyre J. T. (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. neural Transm. 91: 255-269.
13. Hoffman P. L., Grant K. A., Snell L. D., Reinlib L., Iorio K. and Tabakoff B. (1992) NMDA receptors: role in ethanol withdrawal seizures. Ann. N.Y. Acad. Sci. 654: 52-60.
14. Hopfer U., Nelson K., Perrotto J. and Isselbacher K. J. (1973) Glucose transport in isolated brush border membranes from rat small intestine. J. biol. Chem. 248: 25-32.
15. Klockgether T. and Turski L. (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci. 12: 285-286.
16. Li J. -H., Bigge C. F., Williamson R. M., Borosky S. A., Vartanian M. G. and Ortwine D. F. (1995) Potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonists are substrates for a neutral amino acid uptake system in Chinese hamster ovary cells. J. med. Chem. 38: 1955-1965.
17. Lipton S. A., Sucher N. J., Kaiser P. K. and Dreyer E. B. (1991) Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron 7: 111-118.
18. Löscher W. and Schmidt D. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2: 145-181.
19. Loschmann P. A., Lange K. W., Kunow M., Rettig K. J., Jähnig P., Honore T., Turski L., Wachtel H., Jenner P. and Marsden C. D. (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J. neural Transm. 3: 203-213.
20. Lowe D. A., Emre M., Frey P., Kelly P. H., Malanowski J., McAllister K. H., Neijt H. C., Rüdeberg C., Urwyler S., White T. G. and Herrling P. L. (1994) The pharmacology of SDZ EAA 494, a competitive NMDA antagonist. Neurochem. Int. 25: 583-600.
21. Lowe I. P., Robins E. and Eyerman G. S. (1958) The fluorometric measurement of glutamic decarboxylase and its distribution in brain. J. Neurochem. 3: 8-18.
22. Mao J., Price D. D., Hayes R. L., Lu J. and Mayer D. J. (1992) Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res. 598: 271-278.
23. Meldrum B. and Garthwaite J. (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11: 379-387.
24. Mennini T., Miari A., Presti M. L., Rizzi M., Samanin R. and Vezzani A. (1994) Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. Eur. J. Pharmacol. 271: 93-101.
25. Müller W., Kipfer P., Lowe D. A. and Urwyler S. (1995) Syntheses of biphenyl analogues of AP7, a new class of competitive N-methyl-D-aspartate (NMDA) receptor antagonists. Helv. Chim. Acta 78: 2026-2035.
26. Oldendorf W. H. and Szabo J. (1976) Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am. J. Physiol. 230: 94-98.
27. Olney J. M., Labruyere J. and Price M. T. (1989) Pathological changes induced in cerebrocortical neurons by phenylcyclidine and related drugs. Science 244: 1360-1362.
28. Olney J. M., Labruyere J., Wang G., Wozniak D. F., Price M. T. and Sesma M. A. (1991) NMDA antagonist neurotoxicity: Mechanisms and prevention. Science 254: 1515-1518.
29. Park C. K., McCulloch J., Kang J. K. and Choi C. R. (1992) Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat. Neurosci. Lett. 147: 41-44.
30. Ripley T. L., Morris J., Butterworth A. R., Watson W. P. and Little H. J. (1992) Effects of competitive NMDA antagonists, given concurrently with ethanol, on the withdrawal syndrome and the development of ethanol tolerance. Br. J. Pharmacol. 107: 246P.
31. Sauer D., Allegrini P. R., Thedinga K. H., Massieu L., Amacker H. and Fagg G. E. (1992) Evaluation of quinolinic acid induced excitotoxic neurodegeneration in rat striatum by quantitative magnetic resonance imaging in vivo. J. Neurosci. Meth. 42: 69-74.
32. Sauter A. and Rudin M. (1986) Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 17: 1228-1234.
33. Sauter A. and Rudin M. (1991) Visualization and quantification of quinolinic acid lesions in rat brain by magnetic resonance imaging (MRI). Experientia 47: A5.
34. Sauter A. and Rudin M. (1995) Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke. J. Pharmacol. exp. Ther. 274: 1008-1013.
35. Schmutz M., Portet C., Jeker A., Klebs K., Vassout A., Allgeier H., Heckendorn R., Fagg G. E., Olpe H. R. and Van Riezen H. (1990) The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedeberg's Arch. Pharmacol. 342: 61-66.
36. Seltzer Z., Dubner R. and Shir Y. (1990) A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
37. Smith G. D., Wiseman J., Harrison S. M., Elliot P. J. and Birch P. J. (1994) Pretreatment with MK-801, a non-competitive NMDA antagonist, prevents development of mechanical hyperalgesia in a rat model of chronic neuropathy, but not in a model of chronic inflammation. Neurosci. Lett. 165: 79-83.
38. Susel Z., Engber T. M., Kuo S. and Chase T. N. (1991) Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease. Neurosci. Lett. 121: 234-238.
39. Sveinbjornsdottir S., Sander J. W. A. S., Upton D., Thompson P. J., Patsalos P. N., Hirt D., Emre M., Lowe D. and Duncan J. S. (1993) The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16: 165-174.
40. Svensson A., Carlsson A. and Carlsson M. L. (1992) Differential locomotor interactions between dopamine D1/ D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J. neural Transm. 90: 199-217.
41. Tamura A., Graham D. I., McCulloch J. and Teasdale G. M. (1981) Focal cerebral ischemia in the rat. 1. Description of technique and early pathological consequences following middle cerebral artery occlusion. J. cerebr. Blood Flow Metab. 1: 53-60.
42. Tiseo P. J. and Inturrisi C. E. (1993) Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614. J. Pharmacol. exp. Ther. 264: 1090-1096.
43. Tsai G., Gastfriend D. R. and Coyle J. T. (1995) The glutamatergic basis of human alcoholism. Am. J. Psych. 152: 332-340.
44. Urwyler S., Laurie D., Lowe D. A., Meier C. L. and Müller W. (1996) Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid: a novel class of potent competitive N-methyl-D-aspartate antagonists - I. Pharmacological characterization in vitro. Neuropharmacology 35: 643-654.
45. Yamamoto T. and Yaksh T. L. (1992) Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 49: 121-128.
46. Wiederhold K. H. and Palacios J. M. (1990) Receptor autoradiography and 2-deoxyglucose techniques in neuroscience. J. Microscopy 157: 335-347.